ESR1 and cancer: We found that this strategy results in modest improvement in outcomes, and certain subgroups (older patients, no chemotherapy, absence of any cancer involvement of the organs, certain mutations like ESR1 mutations, and non-use of palbociclib as the CDK4/6i) did better.